Get started
KUROS BIOSCIENCES AG CHF0.10(POST SPLIT)KUROS BIOSCIENCES AG CHF0.10(POST SPLIT)KUROS BIOSCIENCES AG CHF0.10(POST SPLIT)

KUROS BIOSCIENCES AG CHF0.10(POST SPLIT)

No trades
See on Supercharts
Overview
Financials News Ideas Technicals Forecast

0RHR chart

Upcoming earnings

Next report date
Report period
H1 2024
EPS estimate
—
Revenue estimate
‪27.00 M‬CHF

Key stats

Market capitalization
‪239.84 M‬CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.38CHF
Net income (FY)
‪−13.73 M‬CHF
Revenue (FY)
‪33.56 M‬CHF
Shares float
‪21.62 M‬
Beta (1Y)
1.98

About KUROS N

Sector
Health Technology
Industry
Biotechnology
CEO
Christopher T. Fair
Website
kurosbiosciences.com
Headquarters
Schlieren
Employees (FY)
5
Founded
2000
ISIN
CH0325814116
FIGI
BBG00JYV5X59
Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals, and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment offers Fibrin-PTH, a drug-biologic combination which promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The Legacy portfolio segment is involved in all other products that do not belong to the group's core business strategy. The company was founded by Didier Cowling in 2000 and is headquartered in Schlieren, Switzerland.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 0RHR is 6.91 CHF — it has decreased by 0.68% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) stocks are traded under the ticker 0RHR.
KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) is going to release the next earnings report on Aug 7, 2024. Keep track of upcoming events with our Earnings Calendar.
0RHR stock is 2.51% volatile and has beta coefficient of 1.98. Check out the list of the most volatile stocks — is KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) there?
0RHR earnings for the last quarter are −0.30 CHF per share, whereas the estimation was −0.38 CHF resulting in a 22.22% surprise. The estimated earnings for the next quarter are −0.33 CHF per share. See more details about KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) earnings.
KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) revenue for the last quarter amounts to ‪12.90 M‬ CHF despite the estimated figure of ‪9.40 M‬ CHF. In the next quarter revenue is expected to reach ‪18.70 M‬ CHF.
Yes, you can track KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) financials in yearly and quarterly reports right on TradingView.
0RHR stock has fallen by 10.19% compared to the previous week, the month change is a 17.46% rise, over the last year KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) has showed a 437.47% increase.
0RHR net income for the last quarter is ‪−8.68 M‬ CHF, while the quarter before that showed ‪−5.05 M‬ CHF of net income which accounts for −71.71% change. Track more KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) financial stats to get the full picture.
Today KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) has the market capitalization of ‪252.78 M‬, it has increased by 10.93% over the last week.
No, 0RHR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0RHR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) stock right from TradingView charts — choose your broker and connect to your account.
0RHR reached its all-time high on Feb 9, 2018 with the price of 9.93 CHF, and its all-time low was 1.28 CHF and was reached on Mar 16, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 29, 2024, the company has 5.00 employees. See our rating of the largest employees — is KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) stock shows the buy signal. See more of KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) future price: according to them, 0RHR price has a max estimate of 7.00 CHF and a min estimate of 7.00 CHF. Read a more detailed KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) forecast: see what analysts think of KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) EBITDA is ‪−6.15 M‬ CHF, and current EBITDA margin is −18.33%. See more stats in KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) financial statements.